TLTF.F Stock Overview
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Theralase Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.13 |
| 52 Week High | CA$0.24 |
| 52 Week Low | CA$0.11 |
| Beta | 1.59 |
| 1 Month Change | -13.41% |
| 3 Month Change | -2.92% |
| 1 Year Change | -25.97% |
| 3 Year Change | -35.25% |
| 5 Year Change | -66.75% |
| Change since IPO | -28.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| TLTF.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 7.4% | -2.9% | -3.1% |
| 1Y | -26.0% | 2.1% | 20.9% |
Return vs Industry: TLTF.F underperformed the US Medical Equipment industry which returned 3.1% over the past year.
Return vs Market: TLTF.F underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| TLTF.F volatility | |
|---|---|
| TLTF.F Average Weekly Movement | 12.1% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TLTF.F's share price has been volatile over the past 3 months.
Volatility Over Time: TLTF.F's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Roger Dumoulin-White | www.theralase.com |
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer.
Theralase Technologies Inc. Fundamentals Summary
| TLTF.F fundamental statistics | |
|---|---|
| Market cap | US$30.70m |
| Earnings (TTM) | -US$3.32m |
| Revenue (TTM) | US$776.43k |
39.5x
P/S Ratio-9.3x
P/E RatioIs TLTF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLTF.F income statement (TTM) | |
|---|---|
| Revenue | CA$1.07m |
| Cost of Revenue | CA$508.17k |
| Gross Profit | CA$562.13k |
| Other Expenses | CA$5.13m |
| Earnings | -CA$4.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.019 |
| Gross Margin | 52.52% |
| Net Profit Margin | -427.06% |
| Debt/Equity Ratio | 0% |
How did TLTF.F perform over the long term?
See historical performance and comparison